Weiming Xia, PhD

Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Xia completed his graduate studies at the University of Texas Medical School at Houston where he earned his MS and PhD degrees (Biochemistry and Molecular Biology). He completed his postdoctoral training in Alzheimer’s disease (AD) at Brigham and Women’s Hospital, Harvard Medical School. In 1999 he became Assistant Professor of Neurology at Harvard Medical School and established a NIH-funded research lab to study AD. In 2012 he joined Department of Veterans Affairs Bedford VA Medical Center, and he leads an independent lab to explore molecular mechanism and biomarkers for AD.

Dr. Xia’s research interests involve target identification, characterization, validation and early stage drug development, with exploration of clinical biomarkers for AD. He has established multiple platforms to quantify pathological proteins like amyloid ß protein (Aß), Tau, neuroinflammatory factors, and related biomarkers. He also develops Mass Spectrometry-based analytic approaches to explore biomarkers for AD and other central nervous system disorders.

Publications

  • Published 9/25/2023

    Aguilar BJ, Miller D, Jasuja G, Li X, Shishova E, O'Connor MK, Nguyen A, Morin P, Berlowitz D, Zhang R, Monfared AAT, Zhang Q, Xia W. Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer's Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System. Neurol Ther. 2023 Dec; 12(6):2067-2078. PMID: 37747662.

    Read at: PubMed

  • Published 5/11/2023

    Chung J, Sahelijo N, Maruyama T, Hu J, Panitch R, Xia W, Mez J, Stein TD, Saykin AJ, Takeyama H, Farrer LA, Crane PK, Nho K, Jun GR. Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles. Alzheimers Dement. 2023 Nov; 19(11):5173-5184. PMID: 37166019.

    Read at: PubMed

  • Published 3/18/2023

    Morin PJ, Zhang Q, Xia W, Miller D, Querfurth H, Tahami Monfared AA. Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer's Disease. Neurol Ther. 2023 Jun; 12(3):721-726. PMID: 36933140.

    Read at: PubMed

  • Published 1/20/2023

    Kirsch D, Shah A, Dixon E, Kelley H, Cherry JD, Xia W, Daley S, Aytan N, Cormier K, Kubilus C, Mathias R, Alvarez VE, Huber BR, McKee AC, Stein TD. Vascular injury is associated with repetitive head impacts and tau pathology in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2023 Jan 20; 82(2):127-139. PMID: 36617181.

    Read at: PubMed

  • Published 1/1/2023

    Vig V, Garg I, Tuz-Zahra F, Xu J, Tripodis Y, Nicks R, Xia W, Alvarez VE, Alosco ML, Stein TD, Subramanian ML. Vitreous Humor Biomarkers Reflect Pathological Changes in the Brain for Alzheimer's Disease and Chronic Traumatic Encephalopathy. J Alzheimers Dis. 2023; 93(3):1181-1193. PMID: 37182888.

    Read at: PubMed

Education

  • University of Texas Health Science Center at Houston, PhD
  • University of Texas Health Science Center at Houston, MS
  • Fudan University, BS